Vehicle, inactive or scrambled sequence, and pathway-positive controls for a peptide cell assay cannot be chosen from the abstracts reviewed here. As of 30 September 2026, these four papers are human observational studies with immunoassay readouts of peptides or peptide-reactive autoantibodies. They do not isolate solvent, sequence dependence, or whether cultured cells can respond.
What “control” meant in these studies
Here a control is a person without the clinical state under study. That contrast does not replace solvent-matched wells, an inactive analog, or a stimulus that shows the same cellular pathway can respond.
A cross-sectional endodontic study (15 July 2026) enrolled 52 adults indicated for primary endodontic treatment: 26 with dental pain and 26 painless controls with a Verbal Rating Scale score of 0. Pulp and unstimulated saliva were measured by ELISA. Pulp calcitonin gene-related peptide (CGRP) was higher in the pain group (p = 0.007; η² = 0.146), as was salivary substance P (p = 0.044; η² = 0.080); pulp substance P and salivary CGRP were not significantly different (p > 0.05). Pain severity correlated with pulp CGRP and salivary substance P, not with histopathological inflammation grade. Salivary markers were not considered direct surrogates of pulpal neuropeptide activity (endodontic ELISA study).
A seborrheic dermatitis case–control study (9 July 2026) compared 51 patients with 40 age- and sex-matched healthy controls. Overall, serum CGRP and neuropeptide Y by ELISA did not differ significantly between groups. Patients with moderate–severe disease had higher levels than those with mild disease (p < 0.01), and both peptides correlated with Seborrheic Dermatitis Area and Severity Index scores (p < 0.001). Perceived Stress Scale-14 scores were higher in patients. The same abstract also states that no significant relationship was observed between the neuropeptides and disease severity, so the retrieved text is not internally consistent on severity (seborrheic dermatitis ELISA study). Neither paper describes a cell monolayer, matched solvent, scrambled peptide, or pharmacological agonist.
A nested case–control analysis (1 June 2026) in the Japan Public Health Center-based Prospective Study measured plasma autoantibodies, including anti-peptide specificities, in 371 incident stroke cases and 371 age-, sex-, and community-matched controls. After adjustment for major cardiovascular risk factors, several autoantibodies were associated with total stroke (highest versus lowest quartile odds ratios ≥1.63); the pattern was weaker for ischemic stroke and was not observed for hemorrhagic stroke. Matching is not a sequence-inactive or pathway-positive control in a cell assay (JPHC nested case–control study).
A Taiwan cross-sectional study (1 August 2026) enrolled 98 rheumatoid arthritis patients and 200 healthy controls and compared two commercial chikungunya ELISA kits with an in-house neutralization assay. Neutralizing antibodies were found in 2 of 98 patients and in none of the controls (Fisher’s exact p = 0.107; chi-square p = 0.043). Both neutralization-positive patients were negative on Abcam and Euroimmun IgM and IgG ELISAs. Agreement with each IgG ELISA was poor (κ = 0); the IgM kits disagreed with each other (κ = −0.38). The study was not sufficiently powered to establish a causal association (chikungunya serology study).
Decision table: which comparator answers which question
Clinical matching, kit choice, and cell-assay controls are not interchangeable. These abstracts do not report vehicle, scrambled-sequence, or cell-assay positive controls.
| Comparator | What it isolates here | When it misleads |
|---|---|---|
| Vehicle (solvent-matched wells) | Not reported | A painless or healthy person does not test solvent, diluent, or handling effects on cells. |
| Inactive or scrambled sequence | Not reported | Plasma anti-peptide antigens, or native CGRP or substance P in fluids, do not show that a test peptide’s sequence is required for a cellular readout. |
| Pathway-positive control in cells | Not reported | An ELISA result or a high clinical peptide value does not show that cells could respond. Neutralization-positive chikungunya samples were ELISA-negative. |
| Painless or healthy human comparators | Between-person disease contrast | A null overall difference (serum CGRP and neuropeptide Y; pulp substance P; salivary CGRP) can look like “no biology” if the matrix or subgroup is wrong. Saliva did not track pulp. |
| Age-, sex-, community-matched nested controls | Stroke association after risk-factor adjustment | Matching does not validate a cellular mechanism or on-target peptide activity. |
| Second immunoassay or neutralization | Method agreement | Using one assay as the “positive control” for another can create or erase a signal. Fisher’s exact and chi-square tests also changed apparent significance in an underpowered comparison. |
How to match vehicle, whether an inactive analog is inert, and which stimulus proves cells can respond are not specified here. As of 30 September 2026, a remaining question is how those three control classes behave in the same cultured-cell peptide experiment.
Before borrowing a published “control” into a cell-assay plan, confirm the model is cells; a solvent-matched condition is reported; sequence dependence used an inactive analog; competence was shown with a stimulus in the same system; and matrix or kit discordance is treated as a warning that the readout, not only the peptide, can generate the result.
Frequently Asked Questions
Do these abstracts specify a vehicle for peptide cell work?
No. They do not report cultured-cell assays or solvent-matched vehicle conditions.
Is a commercial ELISA reactive result a positive control for a peptide cell assay?
Not in these papers. In the chikungunya serology study, the two neutralization-positive rheumatoid arthritis samples were negative on both commercial IgM and IgG ELISAs, and agreement with neutralization was poor (κ = 0). That is a method-comparison problem, not evidence that a cell assay was competent.
Explore Further
Browse our research peptide catalog and review third-party lab reports & COAs for published batches.
---
Research use only. The information above is provided for educational and laboratory research purposes only. The compounds discussed are not approved for human or veterinary use, diagnosis, treatment, or the prevention of any disease. Nothing here is medical advice.